Stocktoria
Rezolute, Inc. RZLT
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2011-12-23
Rezolute, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $61.5M | $55.7M | $43.8M | $32.5M | $15.0M |
| Operating income | -$79.9M | -$70.4M | -$56.0M | -$41.8M | -$22.9M |
| Interest expense | — | — | — | — | $375,000 |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$74.4M | -$68.5M | -$51.8M | -$41.1M | -$20.9M |
| EPS (diluted) | $-0.98 | $-1.33 | $-1.01 | $-2.32 | $-2.72 |
| Operating cash flow | -$69.1M | -$57.4M | -$44.5M | -$39.6M | -$20.4M |
| Free cash flow | — | — | -$44.6M | — | — |
| Cash & equivalents | $94.1M | $70.4M | $16.0M | $150.4M | $41.0M |
| Total assets | $175.5M | $132.7M | $123.7M | $152.4M | $42.6M |
| Total liabilities | $13.4M | $11.7M | $7.5M | $2.9M | $16.5M |
| Shareholders' equity | $162.1M | $121.0M | $116.2M | $149.5M | $26.1M |
Source: SEC EDGAR filings · CIK 0001509261 · as of 2025-06-30. Facts from filings plus Stocktoria's own computed scores — not investment advice.